Misplaced Pages

Evobrutinib

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is an old revision of this page, as edited by Innerstream (talk | contribs) at 15:37, 24 December 2024 (new page). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 15:37, 24 December 2024 by Innerstream (talk | contribs) (new page)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound
Evobrutinib
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
PubChem CID
DrugBank
UNII
KEGG
Chemical and physical data
FormulaC25H27N5O2
Molar mass429.524 g·mol
3D model (JSmol)
SMILES
  • C=CC(=O)N1CCC(CC1)CNC2=NC=NC(=C2C3=CC=C(C=C3)OC4=CC=CC=C4)N

Evobrutinib is an experimental drug being studied for the treatment of encephalomyelitis and multiple sclerosis. It is an inhibitor of Bruton's tyrosine kinase.

References

  1. "Evobrutinib". AdisInsight.
  2. . doi:10.1177/13524585241234783. {{cite journal}}: Cite journal requires |journal= (help); Missing or empty |title= (help)
  3. . doi:10.1016/S1474-4422(24)00328-4. {{cite journal}}: Cite journal requires |journal= (help); Missing or empty |title= (help)
  4. "Evobrutinib". Multiple Sclerosis Trust.
Categories:
Evobrutinib Add topic